Sounds as if VLGC is going to get some help from BMY in the marketing of PhenoSense. Should be quite helpful to sales unless I'm missing something here. ...which is quite possible. ;-)
Ian.
+++++++++++
> November 2, 2000
>
> VIROLOGIC AND BRISTOL-MYERS SQUIBB ENTER HIV SCIENTIFIC AND EDUCATIONAL
> COLLABORATION
>
> SOUTH SAN FRANCISCO, CA - ViroLogic, Inc. (NASDAQ: VLGC) today announced
> an agreement with Bristol-Myers Squibb Company (NYSE: BMY) to jointly
> educate physicians about HIV resistance testing and conduct important new
> drug resistance research.
>
> Under the agreement, Bristol-Myers Squibb and ViroLogic will sponsor a
> series of Continuing Medical Education programs for physicians on the
> topics of HIV therapy and drug resistance. The intent of the programs is
> to have prominent academic and community-based clinicians, along with
> distinguished researchers from industry, present the most up-to-date
> scientific and clinical data on resistance testing and its role in patient
> management.
>
> "Physicians are increasingly turning to drug resistance testing to manage
> HIV infection," said Bill Young, Chairman and CEO of ViroLogic. "Our
> collaboration will help prepare physicians to take advantage of this
> important new technology - to anticipate and respond to drug resistance,
> avoid ineffective drugs, and in many cases improve patient outcomes."
>
> As part of the agreement announced today, ViroLogic will also collaborate
> with Bristol-Myers Squibb on retrospective and prospective scientific
> studies on HIV therapy and resistance. The studies will employ
> ViroLogic's PhenoSense(tm) HIV resistance test and will include research
> on Bristol-Myers Squibb HIV drugs Videx® (didanosine) and Zerit®
> (stavudine). |
